Abstract | RATIONALE: OBJECTIVE: METHOD AND RESULTS: Tests for cross-substitution in which isoarecolone is substituted for nicotine [0.3 mg/kg/infusion (inf)] self-administration suggest isoarecolone to have nominal reinforcing properties (0.3 or 1.0 mg/kg/inf); intake of isoarecolone declined over three test sessions in which responding was no different from saline extinction, and behaviour was reinstated by re-presenting nicotine. In a model of nicotine-seeking behaviour, rats having been extinguished by removal of nicotine (0.03 mg/kg/inf) and associated cues, the presentation of priming doses of nicotine (0.1-0.4 mg/kg s.c.) with the cues robustly reinstated responding of nicotine-seeking behaviour. Tests with priming doses of isoarecolone (1-20 mg/kg s.c.) shown previously to generalise to nicotine in discrimination tests produced significant levels of reinstatement but the responses were significantly less compared to nicotine-induced reinstatement. CONCLUSION: Overall, these results suggest that isoarecolone with its unique profile of behavioural activity should be further examined for treating chronic diseases that are characterised by attentional dysfunction.
|
Authors | Mohammed Shoaib |
Journal | Psychopharmacology
(Psychopharmacology (Berl))
Vol. 188
Issue 2
Pg. 252-7
(Oct 2006)
ISSN: 0033-3158 [Print] Germany |
PMID | 16932923
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Nicotinic Agonists
- Receptors, Nicotinic
- isoarecolone
- Arecoline
- Nicotine
|
Topics |
- Animals
- Arecoline
(analogs & derivatives, pharmacology, therapeutic use)
- Behavior, Animal
(drug effects)
- Disease Models, Animal
- Male
- Nicotine
(administration & dosage)
- Nicotinic Agonists
(pharmacology, therapeutic use)
- Rats
- Rats, Inbred Strains
- Receptors, Nicotinic
(metabolism)
- Self Administration
- Tobacco Use Disorder
(drug therapy, metabolism)
|